ArQule (NASDAQ:ARQL) and Editas Medicine (EDIT) Financial ContrastThe Ledger GazetteIt is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic ac… Continue reading
New AtlasCRISPR tech brews hopless beer with hoppy tasteNew AtlasBiologists at the University of California, Berkeley have used CRISPR technology to create a hop-free brew that still has all the flavor and aroma of conventional beer. By replacing the h… Continue reading
WFSB |
Study tests using stem cell therapy to treat canine arthritis
WFSB PHILADELPHIA (KYW-TV) — There’s a new kind of stem cell therapy that is being tested for dogs who suffer from arthritis. Just like people, dogs can get achy joints, caused by arthritis, and just like with people, treatments don’t always work. Now … |
WFSB |
Study tests using stem cell therapy to treat canine arthritis – WSMV.com
WSMV Nashville PHILADELPHIA (KYW-TV) — There’s a new kind of stem cell therapy that is being tested for dogs who suffer from arthritis. Just like people, dogs can get achy joints, caused by arthritis, and just like with people, treatments don’t always work. Now … Study tests using stem cell therapy to treat canine arthritisWFSB |
WFSB |
Study tests using stem cell therapy to treat canine arthritis – CBS46 …
CBS46 News Atlanta There’s a new kind of stem cell therapy that is being tested for dogs who suffer from arthritis. Study tests using stem cell therapy to treat canine arthritisWFSB |
BBC News |
How I’m feeling after my MS ‘body reboot’
BBC News The initial stage of the trial was aimed at showing that MS patients could safely undergo chemotherapy followed by a stem cell transplant using the patient’s own cells – the building blocks of the immune system. The process is known as a non … |
pulse |
S. Korea’s Binex invests in CAR–T therapy developer PeproMene Bio in US
pulse Binex Co., South Korea’s biomedicines developer and contract manufacturing organization (CMO), has invested $10 million in PeproMene Bio Inc., a U.S.-based developer of novel immune-oncology therapies such as chimeric antigen receptor T cell (CAR-T … |
pulse |
S. Korea’s Binex invests in CAR–T therapy developer PeproMene Bio in US
pulse Binex Co., South Korea’s biomedicines developer and contract manufacturing organization (CMO), has invested $10 million in PeproMene Bio Inc., a U.S.-based developer of novel immune-oncology therapies such as chimeric antigen receptor T cell (CAR-T … |